New Stage 4 Colon Cancer Alternative Cancer Treatment and Natural

New Stage 4 Colon Cancer Alternative Cancer Treatment and Natural Cancer treatment using Natural Ki

Immunotherapy: Powerful New Weapon Against Stage 4 Colon and Stage 4 Cancers With Advanced Natural Cancer Treatment and Alternative Cancer Treatment

Immunotherapy is undisputedly an innovative premier medical strategy that relies on the human immune system to conquer disease. Theoretically over the last 30 odd years, extensive research conducted by teams of physicians and scientists has proven that this venue is clinically successful for a wide range of diseases. Advances in adoptive immunotherapy, which concentrates on the expansion and infusion of specific disease-fighting white blood cells in patients, have boosted this science to peak performance in terms of being an effective treatment for viral diseases, colon cancer, and even stage 4 cancer types.


As time goes by, we can expect to see the importance of immunotherapy grow, particularly in late stage colon cancer, where patients experience metastasis and targeting the cancer as it spreads becomes even more important. To date, stage 4 colon cancer is not much more than chemo and radiation. The statistics are so grim that renowned care providers would not dare report survival data beyond the first couple of years as it is more sobering than promising.

That being said, new immunotherapy treatments are bringing new hope as they deliver a key part of the treatment puzzle - along with better results and quality of life for patients.

Stage 4 Colon Cancer: Natural Killer and Natural Killer T Cells - Typically Depressed in Stage 4 Colon Cancer Patients Data to Support Alternative Caner Treatment and Natural Cancer Treatment

In a study1 of 102 colorectal cancer patients undergoing resections; 18 of them had recurrences within two years of surgery. In all 18, there was significant evidence of "significantly lower preoperative NK cytotoxicity than disease-free patients." Low preoperative NK cytotoxicity was predictive of recurrence in this cohort of patients.1

And in another study2 with nearly 200 subjects, 49 of which suffered with colon cancer in addition to 149 healthy controls, it was observed that Natural Killer levels in colon cancer patients were significantly lower than those of the healthy control group.

Moreover, it has been shown3 that untreated patients with colon cancer have suppressed Natural Killer and Lymphokine-activated killer cells - particularly in late stage patients. These patients were also found to have compromised interferon-gamma producing activities.

NK cell activity serves as a strong prognostic factor for distant metastasis following surgery for colon cancer. In a study4 with 140 colon cancer patients in curatively operated stage I-III diseases, preoperative NK cell activity of 20 percent or less correlated with poor survival. This lower NK activity was also associated with distant metastases, while attenuated NK cell activity was a significant parameter for predicting distant metastasis following curative surgery.

Further evidence5 suggests that pretreatment levels of NK cytotoxicity in patients are significantly related to overall survival, progression-free survival, and response rate. Moreover, it has also been observed that colon cancer patients who are 6 to 12 months after tumor resection, have shown a rise in spontaneous, antibody-induced, and PHA-induced cytotoxicity levels - significantly higher than those found in age-matched controls of healthy individuals.

Sadly, conventional medicine has virtually ignored this type of immunotherapy ... until now.

Astounding Progress in Treating Stage 4 Colon Cancer and Other Stage 4 Cancers with Proprietary Immunotherapy Breakthrough Alternative Cancer Treatment and Natural Cancer Treatment

Recently, a bevy of researchers have touted the successful clinical use of natural killer cells (NKs) and natural killer T cells (NKTs) in treating patients with various malignancies.8,9 While NKs and NKTs are commonly found circulating in the body in minimal amounts, they possess the ability to identify and kill both tumor cells and virally infected cells, and are a major initial defense of our immune system. Without question, patients with colon cancer and stage 4 cancers are often found to be deficient in production of these powerful cells. Over the last 20 years, a number of studies have described NK dysfunction in colon cancer patients.10-12

Specifically, NKs from these patients show a lesser ability to destroy tumor cells in laboratory tests than NKs from healthy patients.10-12 NKs from later stage patients were dramatically more dysfunctional compared to early stage patients with no metastases.10,11 Further, NKs from patients with more advanced disease had an impaired response to interferon, a major growth factor for NK cells.10 T lymphocytes from such patients also do not respond well to stimulatory factors.12 The amount and function of NKT cells have also been under investigation in colon cancer patients.13 NKT numbers in these patients were significantly reduced compared to healthy controls and patients with other cancer types; further, NKTs in these patients were less responsive to short-term stimulation, yet were still capable of substantial expansion.13 Such research cumulatively suggests that colon cancer patients experience an immune suppression that worsens as disease progresses. However, cells with anti-tumor activity can indeed be expanded from these patients for worthy use in clinical immunotherapy regimens.

It is important to note that expansion of natural killer cells is not the same, in process or effect, as taking a product or providing an intravenous nutrient or substance to increase NK cells in the patient. Such methods are far inferior to the targeted, expansion method.

Natural Killer and Natural Killer T Cells are Depressed in Stage 4 Colon Cancer Patients the data is clear Alternative Cancer Treatment and Natural Cancer Treatment Provides Important Options

In a study1 of 102 colorectal cancer patients undergoing resections; 18 of them had recurrences within two years of surgery. In all 18, there was significant evidence of "significantly lower preoperative NK cytotoxicity than disease-free patients." Low preoperative NK cytotoxicity was predictive of recurrence in this cohort of patients.1

And in another study2 with nearly 200 subjects, 49 of which suffered with colon cancer in addition to 149 healthy controls, it was observed that Natural Killer levels in colon cancer patients were significantly lower than those of the healthy control group.

Moreover, it has been shown3 that untreated patients with colon cancer have suppressed Natural Killer and Lymphokine-activated killer cells - particularly in late stage patients. These patients were also found to have compromised interferon-gamma producing activities.

NK cell activity serves as a strong prognostic factor for distant metastasis following surgery for colon cancer. In a study4 with 140 colon cancer patients in curatively operated stage I-III diseases, preoperative NK cell activity of 20 percent or less correlated with poor survival. This lower NK activity was also associated with distant metastases, while attenuated NK cell activity was a significant parameter for predicting distant metastasis following curative surgery.

Further evidence5 suggests that pretreatment levels of NK cytotoxicity in patients are significantly related to overall survival, progression-free survival, and response rate. Moreover, it has also been observed that colon cancer patients who are 6 to 12 months after tumor resection, have shown a rise in spontaneous, antibody-induced, and PHA-induced cytotoxicity levels - significantly higher than those found in age-matched controls of healthy individuals.

This data begs the question why are NK cells and immune system considered vastly more important to conventional cancer treatment protocols? It was questions like this one that led Envita to develop a proprietary new treatment.

Envita Leads the Field in Stage 4 Colon Cancer and Stage 4 Cancer- Targeted Immunotherapy Latest In Alternative Cancer Treatment and Natural Cancer Treatment

Multitudes of published studies have demonstrated the effects of adoptive immune therapy in cancer patients. Envita's renowned medical team assessed the best of these studies and focused on the strengths and weaknesses of each. Their findings established a protocol that incorporates only the best procedures for the expansion and application of cells as a powerful immunotherapy. Our protocols are based on the most recent published research in the field, from some of the most prestigious hospitals and universities in the nation and around the world. However, our treatment has been specially designed to deal specifically with colon cancer and stage 4 cancer patients' immune systems. And the sooner this treatment method is administered to the patient, the quicker improvements are experienced throughout the whole of their treatment.

Envita's Two-fold Stage 4 Colon Cancer and Stage 4 Cancer Immunotherapy Alternative Cancer Treatment and Natural Cancer Treatment That Matte Most

Envita Natural Medical Center in its Mexico office is currently utilizing NK cells and CTLs as immunotherapy Treatment for colon cancer and stage 4 cancer patients. Envita's proprietary immune therapy vaccine is called AAIT (for autologous adoptive immune therapy,) and there are 4 major cell types involved - the great majority being natural killer cells and T cells. The types of cells that make up Envita's treatment are listed below:

Natural killer cells Natural killer T cells Cytokine-induced killer cells Cytotoxic T lymphocytes

The vaccine(s) is compiled by growing a patient's own antitumor immune cells into the billions. These cells are then analyzed for activation markers and tested for their ability to kill colon cancer and other stage 4 cancer cells in the laboratory, then re-infused into the patient.

Enhancing the immune system is a major benefit to fighting colon cancer or other cancers, but this vaccine-driven immunotherapy routine may be added upon through subtraction. Simply put, we can improve results by not only bolstering critical components of the immune system, but simultaneously depleting it of negative factors that impede its functionality. Depleting such negative factors is critical to a patient's success.

It is no secret that cancer cells effect the release of T-regulatory cells, or "negative T cells." The numbers of these cells correlate directly with specific cancer stages - respective to each cancer type. The more advanced the cancer, the higher the T-regulatory cells. These cells block your body's system ability to fight. The immune system is the first and last defense against cancer.

Naturally, by stepping in and acting to deplete these cells along with other key enzymes that block critical immune system, cancer cell-killing action will be expedited exponentially. Imagine your immune system being targeted and ready to go, yet something in your body suddenly applies the brakes. This is in fact what most advanced colon cancer and stage 4 cancer patients are dealing with in regards to high regulatory T cells. Envita's immunotherapy treatment protocols build a targeted vaccine by using the body's most powerful cancer killers, but also depletes the portion of the immune system that inhibits the body from functioning efficiently in such regard.

Case in point, there is no treatment (conventional or alternative) that can be effective in the later stages of cancer if these negative T-cells are not effectively down-regulated.

Unlike other available immunotherapy treatments, Envita's AAIT can be used as a stand-alone. AAIT can also be given in conjunction with other therapies that will act to enhance the effects of cells once they are in the patient. This is a key improvement over many of the published studies in the scientific literature. Envita's AAIT therapy is not just focused on expanding cells in the laboratory; the ultimate goal is to also expand them and keep them activated after they are infused back into the body. Making AAIT next important piece to colon cancer and stage 4 cancer therapy.

AAIT Immunology Available for Stage 4 Colon cancer and Stage 4 Cancer Patients at Envita Mexico Leader in Alternative Cancer Treatment and Natural Cancer Treatment

Envita Natural Medical Center is currently utilizing NK, NKT, and T lymphocytes as supportive immunotherapy for our cancer patients. Envita's therapy is titled AAIT, and increases a patient's own antitumor immune cells into the billions over a span of several weeks. These cells are monitored for activation markers, evaluated for their ability to kill cancer cells in the laboratory, and then subsequently re-infused into the patient. Heralded by scientific research and clinical results, Enivta's AAIT immunotherapy offers a potent option for cancer patients who are dedicated to battling stage 4 colon and other stage 4 cancers while maintaining an intact immune system. Envita administers only superior combinations of conventional and alternative cancer treatment bolstered by advanced natural cancer treatment to help patients get healthier and improve their overall quality of life.

1. Tartter PI, Steinberg B, Barron DM, Martinelli G. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg. 1987 Nov;122(11):1264-8.

2. Balch CM, Tilden AB, Dougherty PA, Cloud GA. Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg. 1983 Aug;198(2):192-9. 3. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg. 2003;20(5):445-51. Epub 2003 Jul 31.

3. Matsunaga H, Kuwahara Y, Kusugami K, Morise K, Shimokata K. Natural killer, lymphokine-activated killer and interferon-gamma producing activities of peripheral blood- and regional lymph node-mononuclear cells in 23 cases of colorectal cancer. Gastroenterol Jpn. 1988 Oct; 23(5):527-33.

4. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg. 2003;20(5):445-51. Epub 2003 Jul 31.

5. Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer. 2003 Jul 10;105(5):717-23.

6. Waller CA, Gill PG, MacLennan IC. Enhancement of lymphocyte-mediated cytotoxicity after tumor resection in patients with colorectal cancer. J Natl Cancer Inst. 1980 Aug;65(2):223-30.

Chronic Fatigue syndrome Envita is one of the leading natural medical centers in the U.S. and abroad. Envita treats a large range of conditions, and our mainly focused areas such as cancer, disease. For more Informations Please Visit Our www.envita.com Website.